-
Lilly’s Foundayo (orforglipron) Significantly Reduced Obstructive Sleep Apnea Severity, Reinforcing Its Potential to Improve Health Beyond Weight Loss
NYSE: $LLY INDIANAPOLIS, Nov. 9, 2026 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide), today announced positive results from ATTAIN-OSA, a Phase 3 clinical program evaluating the efficacy and safety of Foundayo… Source: Read More